| Literature DB >> 31481499 |
Srishti Chakravorty1, Bingyu Yan1, Chong Wang2, Luopin Wang3, Joseph Taylor Quaid1, Chin Fang Lin4, Scott D Briggs1, Joydeb Majumder5, D Alejandro Canaria6, Daniel Chauss7, Gaurav Chopra5, Matthew R Olson6, Bo Zhao2, Behdad Afzali7, Majid Kazemian8,3.
Abstract
Epstein-Barr virus (EBV) is a complex oncogenic symbiont. The molecular mechanisms governing EBV carcinogenesis remain elusive and the functional interactions between virus and host cells are incompletely defined. Here we present a comprehensive map of the host cell-pathogen interactome in EBV-associated cancers. We systematically analyzed RNA sequencing from >1,000 patients with 15 different cancer types, comparing virus and host factors of EBV+ to EBV- tissues. EBV preferentially integrated at highly accessible regions of the cancer genome, with significant enrichment in super-enhancer architecture. Twelve EBV transcripts, including LMP1 and LMP2, correlated inversely with EBV reactivation signature. Overexpression of these genes significantly suppressed viral reactivation, consistent with a "virostatic" function. In cancer samples, hundreds of novel frequent missense and nonsense variations in virostatic genes were identified, and variant genes failed to regulate their viral and cellular targets in cancer. For example, one-third of patients with EBV+ NK/T-cell lymphoma carried two novel nonsense variants (Q322X, G342X) of LMP1 and both variant proteins failed to restrict viral reactivation, confirming loss of virostatic function. Host cell transcriptional changes in response to EBV infection classified tumors into two molecular subtypes based on patterns of IFN signature genes and immune checkpoint markers, such as PD-L1 and IDO1. Overall, these findings uncover novel points of interaction between a common oncovirus and the human genome and identify novel regulatory nodes and druggable targets for individualized EBV and cancer-specific therapies. SIGNIFICANCE: This study provides a comprehensive map of the host cell-pathogen interactome in EBV+ malignancies.See related commentary by Mbulaiteye and Prokunina-Olsson, p. 5917. ©2019 American Association for Cancer Research.Entities:
Mesh:
Year: 2019 PMID: 31481499 PMCID: PMC6891172 DOI: 10.1158/0008-5472.CAN-19-0615
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701